Pneumococcal Vaccines Market
Pneumococcal Vaccines Market is segmented By Product Type (Pneumococcal conjugate vaccine, Pneumococcal polysaccharide vaccine), By End-User (Infants/Young Children, Adults/ Young Adults, Geriatric), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2022-2029.
Pneumococcal Vaccines Market is expected to grow at a CAGR of 8.30% during the forecasting period (2022-2029).
Pneumococcal Vaccines help prevent pneumococcal disease, which is a type of infection caused by Streptococcus pneumonia bacteria. Pneumococcal disease is contagious and can cause severe infections in the lungs, the lining of the brain, invasive pneumococcal disease, concomitant administration.The spinal cord, and blood. It is more common in children, but it’s most likely to cause severe complications in adults. Search for new vaccines is warranted as Streptococcus pneumonia has developed resistance to several available drugs. The genome of Streptococcus pneumoniae has been identified to contain new drug sites, hence aiding in developing newer drugs to treat Pneumococcal diseases.
As per DataM Intelligence, Pneumococcal Vaccines Market study analysis offers an in-depth outlook on the market containing quantitative and qualitative data. It gives an outlook and forecast of the global market based on market segmentation. It also provides global Pneumococcal Vaccines Market size, and growth, along with the latest trends, opportunities, and forecast till 2029 for the global market with esteem to major countries such as the United States, Canada, Brazil, Germany, Italy, Spain, United Kingdom, Russia, European countries, United Arab Emirates, Saudi Arabia, South Africa, Japan, China, India, South Korea, Australia, and rest of the countries over the globe.
Among all regions, the North American region is expected to hold the largest share of the global market over the forecast period. Pneumococcal Vaccines Market in the United States and Canada produces the utmost share. Whereas the European Pneumococcal Vaccines Market is projected to continue its presence globally during the period of 2022- 2029.
Pneumococcal Vaccines Market Scope
|
Metrics |
Details |
|
Market CAGR |
8.30% |
|
Segments Covered |
By Product Type, By End-User, and By Region |
|
Report Insights Covered |
Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
|
Fastest Growing Region |
Asia Pacific |
|
Largest Market Share |
North America |
Recommended vaccines and doses
- It is recommended that all children under age 2 be immunized with the pneumococcal conjugate vaccine (Prevnar 13®) in four doses spread out over slightly more than a year.
- The PPSV23 vaccine that protects against 23 types of pneumococcal bacteria is administered to adults 65 years or older and for kids who are 2 years or older.
Frequently Asked Questions
What is the Projected CAGR value of the Pneumococcal Vaccines Market?
Pneumococcal Vaccines Market is expected to grow at a CAGR of 8.30% during the forecasting period 2022-2029.
Which region controlled the global market during 2022-2029?
North America region Controls the Pneumococcal Vaccines Market during 2022-2029.
Which is the fastest growing region in the Pneumococcal Vaccines Market?
Among all regions, Asia Pacific is the fastest growing market share during the forecast period.